Known safety concerns, contraindications, and risk factors.
Thyroid Malignancy (MTC/MEN2)
Semaglutide is strictly contraindicated for individuals with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2.
Active or Suspected Cancer
Due to the growth-stimulating nature of many peptides, those with active cancer should avoid GHK-Cu and GH secretagogues unless specifically directed by medical supervision.
Wilson's Disease
Individuals with Wilson's Disease must avoid copper-binding peptides like GHK-Cu due to the danger of toxic copper buildup in tissues.
Pregnancy, Breastfeeding, or Under 18
There is insufficient research to establish the safety of peptide therapy for individuals under 18, or those who are pregnant or breastfeeding.
Concurrent Use of Vitamin C, Retinoids, or AHAs with GHK-Cu
Experts recommend avoiding concurrent use of GHK-Cu with Vitamin C, retinoids, or AHAs as these can reduce peptide effectiveness or increase skin barrier irritation.
Blood Sugar Sensitivity / Late-Day IGF-1 Administration
Due to impact on insulin sensitivity, IGF-1 variants should not be administered late in the day to avoid nocturnal blood sugar complications.